The multi-year trial, Oura's first, will test whether ring data on sleep, heart rate and activity lines up with weight loss, HbA1c and staying on treatment.
Recap by typeshit. Full story at Fierce Healthcare.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
Researchers suggest Ozempic and Wegovy could influence hiring decisions and workplace productivity as more Americans take them.
Compounders get a pass on BPC-157, TB-500 and four others if they meet sourcing and reporting rules. The Alliance for Pharmacy Compounding cheers it, while Public Citizen calls it reckless.
Loading…